Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672809 | 0.74 | KMT2A (0.33) | ALDH1A1L3MBTL1HPGDTSHRKDM4E | |
| SCHEMBL8977852 | 0.74 | CHEK1 (0.34) | ALDH1A1L3MBTL1 | |
| SCHEMBL3205487 | 0.74 | AHR (0.41) | CYP11B2ALDH1A1L3MBTL1 | |
| SCHEMBL23421595 | 0.74 | MEN1 (0.36) | ALDH1A1L3MBTL1HPGDTSHRMEN1 | |
| SCHEMBL9769233 | 0.71 | KMT2A (0.33) | ALDH1A1HPGDKDM4EGAAKMT2A | |
| SCHEMBL7915878 | 0.69 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1HPGDTSHRKDM4E | |
| SCHEMBL8014108 | 0.67 | ALDH1A1 (0.37) | ALDH1A1TSHRGAAMEN1KMT2A | |
| SCHEMBL1187776 | 0.66 | — | — | |
| SCHEMBL9769333 | 0.66 | TSHR (0.31) | TSHR | |
| SCHEMBL23029993 | 0.65 | KDM4E (0.41) | ALDH1A1HPGDTSHRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100047321-A1 | SILVER ANTIMICROBIAL COMPOSITION AND USE | EASTMAN KODAK COMPANY | 2010-02-25 | — | — | US | claimed |
| WO-2010021662-A2 | SILVER ANTIMICROBIAL COMPOSITION AND USE | EASTMAN KODAK COMPANY (US) | 2010-02-25 | — | — | WO | claimed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2021058595-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-19 | — | — | US | disclosed |
| EP-3414233-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| US-20100047321-A1 | SILVER ANTIMICROBIAL COMPOSITION AND USE | EASTMAN KODAK COMPANY | 2010-02-25 | — | — | US | disclosed |
| WO-2010021662-A2 | SILVER ANTIMICROBIAL COMPOSITION AND USE | EASTMAN KODAK COMPANY (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | CYP11B2 473/4885ALDH1A1 1813/4885L3MBTL1 3524/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | CYP11B2 211/4885ALDH1A1 1634/4885L3MBTL1 2293/4885 |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | CYP11B2 1635/4885ALDH1A1 3429/4885L3MBTL1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.